Dr. Amy Johnson on Research Into Acalabrutinib as a Treatment for CLL
Amy Johnson, PhD, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196).
Amy Johnson, PhD, associate professor, Hematology, Ohio State University, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196). Acalabrutinib is a selective, irreversible BTK inhibitor designed to improve both the safety and efficacy of BTK inhibitors in CLL.
Johnson says there is currently neither a subtype of patient with CLL that benefits from acalabrutinib, nor is there a subtype that suffers from the treatment.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL
September 16th 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Adaptive NSCLC Trial Misses Target Efficacy, Reaches Clinical Benefit in Some Patients
September 16th 2024The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.
Read More
